PT Kino Indonesia Tbk (IDX:KINO)

Sage Therapeutics Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	4,360,533	4,367,489	4,136,182	3,631,451	3,976,656	4,024,971
Revenue Growth (YoY)	-1.02%	5.59%	13.90%	-8.68%	-1.20%	-13.98%
Cost of Revenue	2,437,624	2,484,388	2,383,032	2,325,810	2,184,246	2,102,905
Gross Profit	1,922,909	1,883,102	1,753,150	1,305,641	1,792,410	1,922,066
Selling, General & Admin	1,695,348	1,662,810	1,495,415	2,029,121	1,632,411	1,709,699
Other Operating Expenses	2,860	2,860	8,517	34,774	29,595	2,592
Operating Expenses	1,739,350	1,695,211	1,504,748	2,063,896	1,571,733	1,712,291
Operating Income	183,559	187,891	248,401	-758,255	220,677	209,775
Interest Expense	-134,772	-144,098	-168,624	-170,735	-156,329	-137,914
Interest & Investment Income	1,680	2,006	2,980	1,764	1,201	4,606
Earnings From Equity Investments	3,134	2,932	-	-	-	-
Currency Exchange Gain (Loss)	-1,868	4,481	-3,306	12,527	-1,429	4,625
Other Non Operating Income (Expenses)	68,026	53,628	39,502	7,852	47,205	49,053
EBT Excluding Unusual Items	119,758	106,840	118,953	-906,847	111,324	130,145
Gain (Loss) on Sale of Investments	-	-	-	-	-	-2,528
Gain (Loss) on Sale of Assets	1,436	1,618	-4,289	6,672	13,588	8,717
Asset Writedown	-1,610	-1,610	-1,005	-16,919	-1,404	-
Other Unusual Items	-	-	-6.74	-	-	-1,175
Pretax Income	119,584	106,848	113,653	-917,094	123,508	135,160
Income Tax Expense	8,758	17,931	36,406	33,195	25,688	21,495
Earnings From Continuing Operations	110,827	88,917	77,247	-950,289	97,820	113,665
Minority Interest in Earnings	-1,132	-2,317	-6,784	-6,737	7,223	31.38
Net Income	109,695	86,599	70,463	-957,026	105,043	113,697
Net Income to Common	109,695	86,599	70,463	-957,026	105,043	113,697
Net Income Growth	57.48%	22.90%	-	-	-7.61%	-78.15%
Shares Outstanding (Basic)	1,368	1,379	1,379	1,393	1,429	1,429
Shares Outstanding (Diluted)	1,368	1,379	1,379	1,393	1,429	1,429
Shares Change (YoY)	-1.21%	-	-1.01%	-2.50%	-	-
EPS (Basic)	80.16	62.81	51.10	-687.06	73.53	79.59
EPS (Diluted)	80.16	62.81	51.10	-687.06	73.53	79.59
EPS Growth	59.42%	22.90%	-	-	-7.61%	-78.15%
Free Cash Flow	321,628	284,895	542,099	18,416	235,772	-452,412
Free Cash Flow Per Share	235.02	206.62	393.16	13.22	165.04	-316.69
Dividend Per Share	-	-	22.000	-	22.000	32.000
Dividend Growth	-	-	-	-	-31.25%	-70.37%
Gross Margin	44.10%	43.12%	42.39%	35.95%	45.07%	47.75%
Operating Margin	4.21%	4.30%	6.01%	-20.88%	5.55%	5.21%
Profit Margin	2.52%	1.98%	1.70%	-26.35%	2.64%	2.83%
Free Cash Flow Margin	7.38%	6.52%	13.11%	0.51%	5.93%	-11.24%
EBITDA	186,283	188,609	88,404,432	-613,270	347,179	307,403
EBITDA Margin	4.27%	4.32%	2137.34%	-16.89%	8.73%	7.64%
D&A For EBITDA	2,724	718	88,156,031	144,985	126,502	97,629
EBIT	183,559	187,891	248,401	-758,255	220,677	209,775
EBIT Margin	4.21%	4.30%	6.01%	-20.88%	5.55%	5.21%
Effective Tax Rate	7.32%	16.78%	32.03%	-	20.80%	15.90%
Advertising Expenses	-	770,875	747,307	851,782	751,824	634,713

Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.